Literature DB >> 28266519

Drugs that lack single-agent activity: are they worth pursuing in combination?

Bishal Gyawali1, Vinay Prasad2,3,4.   

Abstract

Mesh：

Year:  2017        PMID： 28266519     DOI： 10.1038/nrclinonc.2017.27

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  7 in total

1.  Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.

Authors:  Jeffrey L Wolf; David Siegel; Hartmut Goldschmidt; Katharine Hazell; Priscille M Bourquelot; Bourras R Bengoudifa; Jeffrey Matous; Ravi Vij; Margarida de Magalhaes-Silverman; Rafat Abonour; Kenneth C Anderson; Sagar Lonial
Journal:  Leuk Lymphoma       Date:  2012-03-01

2.  Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.

Authors:  Alberto Ocaña; Eitan Amir; Francisco Vera; Elizabeth A Eisenhauer; Ian F Tannock
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

3.  Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Authors:  Meletios Dimopoulos; David S Siegel; Sagar Lonial; Junyuan Qi; Roman Hajek; Thierry Facon; Laura Rosinol; Catherine Williams; Hilary Blacklock; Hartmut Goldschmidt; Vania Hungria; Andrew Spencer; Antonio Palumbo; Thorsten Graef; Joseph E Eid; Jennifer Houp; Linda Sun; Scott Vuocolo; Kenneth C Anderson
Journal:  Lancet Oncol       Date:  2013-09-19       Impact factor: 41.316

4.  A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

Authors:  Jeffrey A Zonder; Ann F Mohrbacher; Seema Singhal; Frits van Rhee; William I Bensinger; Han Ding; John Fry; Daniel E H Afar; Anil K Singhal
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

5.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

Authors:  George W Sledge; Donna Neuberg; Patricia Bernardo; James N Ingle; Silvana Martino; Eric K Rowinsky; William C Wood
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

6.  Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

Authors:  K L Blackwell; M D Pegram; E Tan-Chiu; L S Schwartzberg; M C Arbushites; J D Maltzman; J K Forster; S D Rubin; S H Stein; H J Burstein
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

7.  Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

Authors:  Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Liang Xiu; Andrew Cakana; Trilok Parekh; Jesús F San-Miguel
Journal:  Cancer       Date:  2016-05-18       Impact factor: 6.860
  7 in total
  6 in total

Review 1.  Independent Drug Action in Combination Therapy: Implications for Precision Oncology.

Authors:  Deborah Plana; Adam C Palmer; Peter K Sorger
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

Review 2.  Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.

Authors:  Daphné Morel; Daniel Jeffery; Geneviève Almouzni; Sophie Postel-Vinay; Sandrine Aspeslagh
Journal:  Nat Rev Clin Oncol       Date:  2019-09-30       Impact factor: 66.675

Review 3.  Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Authors:  C S Chim; S K Kumar; R Z Orlowski; G Cook; P G Richardson; M A Gertz; S Giralt; M V Mateos; X Leleu; K C Anderson
Journal:  Leukemia       Date:  2017-11-16       Impact factor: 11.528

Review 4.  Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.

Authors:  Vincent Lemaire; Colby S Shemesh; Anand Rotte
Journal:  J Exp Clin Cancer Res       Date:  2021-10-01

5.  Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity.

Authors:  Jared Foster; Boris Freidlin; E L Korn; Malcolm Smith
Journal:  ESMO Open       Date:  2020-10

6.  Can Any Drug Be Repurposed for Cancer Treatment? A Systematic Assessment of the Scientific Literature.

Authors:  Nicolai Stransky; Peter Ruth; Matthias Schwab; Markus W Löffler
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.